The fusion of Y8 to pembrolizumab enhanced T cell–mediated tumor cell killing, whereas fusion to atezolizumab (anti–PD-L1), which engages its target in trans, failed to improve cytotoxicity (Supplementary Fig. 11). The gene discussed is CD274; the disease is neoplasm.